JP2003514013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514013A5 JP2003514013A5 JP2001537935A JP2001537935A JP2003514013A5 JP 2003514013 A5 JP2003514013 A5 JP 2003514013A5 JP 2001537935 A JP2001537935 A JP 2001537935A JP 2001537935 A JP2001537935 A JP 2001537935A JP 2003514013 A5 JP2003514013 A5 JP 2003514013A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- naltrexone
- nalmefene
- naloxone
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 16
- 229960001736 buprenorphine Drugs 0.000 description 16
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 13
- 229960005297 nalmefene Drugs 0.000 description 13
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 13
- 229960004127 naloxone Drugs 0.000 description 13
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 13
- 229960003086 naltrexone Drugs 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9927359.1 | 1999-11-19 | ||
| GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
| US17620800P | 2000-01-14 | 2000-01-14 | |
| US60/176,208 | 2000-01-14 | ||
| PCT/GB2000/004372 WO2001035942A2 (en) | 1999-11-19 | 2000-11-17 | Analgesic compositions containing buprenorphine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514013A JP2003514013A (ja) | 2003-04-15 |
| JP2003514013A5 true JP2003514013A5 (OSRAM) | 2007-09-27 |
| JP4745576B2 JP4745576B2 (ja) | 2011-08-10 |
Family
ID=26316086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537935A Expired - Fee Related JP4745576B2 (ja) | 1999-11-19 | 2000-11-17 | 医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US6995169B2 (OSRAM) |
| EP (1) | EP1242087B1 (OSRAM) |
| JP (1) | JP4745576B2 (OSRAM) |
| KR (1) | KR100726699B1 (OSRAM) |
| CN (1) | CN100431543C (OSRAM) |
| AR (1) | AR031682A1 (OSRAM) |
| AT (1) | ATE262335T1 (OSRAM) |
| AU (1) | AU777259B2 (OSRAM) |
| BR (1) | BR0015580A (OSRAM) |
| CA (1) | CA2392013C (OSRAM) |
| CO (1) | CO5261517A1 (OSRAM) |
| CZ (1) | CZ303160B6 (OSRAM) |
| DE (1) | DE60009346T2 (OSRAM) |
| DK (1) | DK1242087T3 (OSRAM) |
| ES (1) | ES2214334T3 (OSRAM) |
| GB (1) | GB2356348B (OSRAM) |
| HU (1) | HU229565B1 (OSRAM) |
| IL (2) | IL149580A0 (OSRAM) |
| MX (1) | MXPA02004978A (OSRAM) |
| NO (1) | NO321965B1 (OSRAM) |
| NZ (1) | NZ519023A (OSRAM) |
| PL (1) | PL199727B1 (OSRAM) |
| PT (1) | PT1242087E (OSRAM) |
| RO (1) | RO121174B1 (OSRAM) |
| RU (1) | RU2255737C2 (OSRAM) |
| SI (1) | SI21025B (OSRAM) |
| SK (1) | SK286888B6 (OSRAM) |
| TR (1) | TR200400653T4 (OSRAM) |
| TW (1) | TW550070B (OSRAM) |
| WO (1) | WO2001035942A2 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| DE602004012403T2 (de) | 2003-04-29 | 2009-03-19 | Orexigen Therapeutics, Inc., La Jolla | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| PL2135603T3 (pl) * | 2005-11-22 | 2013-09-30 | Orexigen Therapeutics Inc | Kompozycje i sposoby zwiększania wrażliwości na insulinę |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
| CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
| EP2089010A1 (en) | 2006-10-24 | 2009-08-19 | The John Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
| TW200829235A (en) | 2006-11-09 | 2008-07-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications |
| US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
| GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
| GB2447014A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
| GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| DK2197429T3 (en) * | 2007-09-03 | 2016-05-30 | Nanotherapeutics Inc | Particulate compositions for delivery of poorly soluble drugs |
| US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
| US20110144145A1 (en) * | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| JP6196041B2 (ja) * | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| AU2011346757B2 (en) | 2010-12-22 | 2015-08-20 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| MX361757B (es) | 2011-09-19 | 2018-12-13 | Orexo Ab | Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides. |
| CA2875056C (en) | 2012-06-06 | 2024-03-26 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
| US20150342946A1 (en) | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9216175B2 (en) * | 2013-09-10 | 2015-12-22 | Insys Pharma, Inc. | Sublingual buprenorphine spray |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| JP6797691B2 (ja) * | 2014-04-22 | 2020-12-09 | 大塚製薬株式会社 | ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途 |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| WO2021158957A1 (en) * | 2020-02-05 | 2021-08-12 | Summit Biosciences Inc. | Drug products for intranasal administration and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
| US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| RU2077326C1 (ru) * | 1992-12-29 | 1997-04-20 | Ярыгин Владимир Никитич | Препарат для анальгезии |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| AU5956001A (en) * | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en not_active Ceased
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active Expired - Fee Related
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514013A5 (OSRAM) | ||
| RU2002116361A (ru) | Анальгезирующие композиции, содержащие бупренорфин | |
| JP2010520183A5 (OSRAM) | ||
| JP2010520186A5 (OSRAM) | ||
| WO2000021515A3 (en) | Intranasal codeine for the rapid suppression of cough and rapid relief of pain | |
| MX2009009131A (es) | Mejoras en y con relacion a composiciones medicinales. | |
| JP2009544619A5 (OSRAM) | ||
| JP2010520185A5 (OSRAM) | ||
| CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
| CA2359812A1 (en) | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | |
| US20110082167A1 (en) | Topical compositions of opioid antagonists and methods for treating skin conditions therewith | |
| EP0377272A3 (en) | Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases | |
| CA2467490A1 (en) | Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
| AUPN603895A0 (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids | |
| WO2006058249A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| JP2009536147A5 (OSRAM) | ||
| MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
| WO2001093852A3 (en) | Method of treating pain using nalbuphine and opioid antagonists | |
| JP2004507496A5 (OSRAM) | ||
| JP2002523370A5 (OSRAM) | ||
| WO2003073981A3 (en) | Novel of cytokine inhibitors | |
| JP2010520184A5 (OSRAM) | ||
| JP2004537500A5 (OSRAM) | ||
| JP2002528502A5 (OSRAM) | ||
| RU2004107501A (ru) | Способ лечения алкоголизма или злоупотребления алкоголем |